Nestlé Health Science Plans Continuum Of Care
Executive Summary
Nestlé’s announcement on May 24 that its new health sciences subsidiary is buying Prometheus Laboratories, a gastrointestinal drug and diagnostic company, takes the food company in a new direction, but also raises questions for pharma.
You may also be interested in...
Nestlé Gets Serious With Seres Deal
The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.
A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
With Traditional Chinese Medicine Deal, Nestle’s Health Science Business Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.